HDL Proteome and Alzheimer’s Disease: Evidence of a Link
Open accessThe DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
Several lines of epidemiological evidence link increased levels of high-density lipoprotein-cholesterol (HDL-C) with lower risk of Alzheimer’s disease (AD). This observed relationship might reflect the beneficial effects of HDL on the cardiovascular system, likely due to the implication of vascular dysregulation in AD development. The atheroprotective properties of this lipoprotein are mostly due to its proteome. In particular, apolipoprotein (Apo) A-I, E, and J and the antioxidant accessory protein paraoxonase 1 (PON1), are the main determinants of the biological function of HDL. Intriguingly, these HDL constituent proteins are also present in the brain, either from in situ expression, or derived from the periphery. Growing preclinical evidence suggests that these HDL proteins may prevent the aberrant changes in the brain that characterize AD pathogenesis. In the present review, we summarize and critically examine the current state of knowledge on the role of these atheroprotective HDL-associated proteins in AD pathogenesis and physiopathology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Harold, D., Abraham, R., Hollingworth, P., Sims, R., Gerrish, A., Hamshere, M. L., Pahwa, J. S., Moskvina, V., Dowzell, K., Williams, A., et al. (2009) · Nature Genetics · doi:10.1038/ng.440 · Cited by 3,326 · cited 2×
“Two genomic wide association studies (GWAS) have identified the CLU gene as a novel risk factor for late-onset AD [98,99], becoming the third most common genetic risk factor after APOE and bridging integrator 1 (BIN1).”
Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
The AIM-HIGH Investigators (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107579 · Cited by 2,911
Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies
Yamazaki, Y., Zhao, N., Caulfield, T. R., Liu, C.-C., & Bu, G. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0228-7 · Cited by 1,425 · cited 3×
“The role of apoE in Aβ processing and deposition is very well known, and has been extensively reviewed elsewhere [58].”
BackgroundInfluentialHDL cholesterol efflux capacity and incident cardiovascular events
Rohatgi, A., Khera, A., Berry, J. D., Givens, E. G., Ayers, C. R., Wedin, K. E., Neeland, I. J., Yuhanna, I. S., Rader, D. R., de Lemos, J. A., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1409065 · Cited by 1,390 · cited 16×
“In fact, a centenarians study in Ashkenazi Jews revealed that plasma HDL-C levels are positively related with cognitive function, determined by the mini-mental state examination (MMSE), an index of cognitive performance [8].”
BackgroundInfluentialAPOE4 leads to blood–brain barrier dysfunction predicting cognitive decline
Montagne, A., Nation, D. A., Sagare, A. P., Barisano, G., Sweeney, M. D., Chakhoyan, A., Pachicano, M., Joe, E., Nelson, A. R., D’Orazio, L. M., et al. (2020) · Nature · doi:10.1038/s41586-020-2247-3 · Cited by 1,281
ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy
Initiative, A. D. N., Shi, Y., Yamada, K., Liddelow, S. A., Smith, S. T., Zhao, L., Luo, W., Tsai, R. M., Spina, S., Grinberg, L. T., et al. (2017) · Nature · doi:10.1038/nature24016 · Cited by 1,220 · cited 2×
“, 2017 [62] In vivo (animal model) ApoE4 worsened the tau-mediated neurodegeneration”
BackgroundSeidah, N. G., Benjannet, S., Wickham, L., Marcinkiewicz, J., Jasmin, S. B., Stifani, S., Basak, A., Prat, A., & Chrétien, M. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0335507100 · Cited by 1,191
Recent global trends in the prevalence and incidence of dementia, and survival with dementia
Prince, M., Ali, G.-C., Guerchet, M., Prina, A. M., Albanese, E., & Wu, Y.-T. (2016) · Alzheimer's Research & Therapy · doi:10.1186/s13195-016-0188-8 · Cited by 876
Dysfunctional HDL and atherosclerotic cardiovascular disease
Rosenson, R. S., Brewer, H. B., Ansell, B. J., Barter, P., Chapman, M. J., Heinecke, J. W., Kontush, A., Tall, A. R., & Webb, N. R. (2016) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2015.124 · Cited by 822 · cited 3×
“Indeed, the functional properties of HDL, and in particular the capacity of HDL to promote cholesterol efflux from macrophages, the first step of the reverse cholesterol transport, is emerging as a better predictor of CVD and in the majority of the cases independently of plasma levels of HDL-C [18,19].”
BackgroundEvacetrapib and cardiovascular outcomes in high-risk vascular disease
Lincoff, A. M., Nicholls, S. J., Riesmeyer, J. S., Barter, P. J., Brewer, H. B., Fox, K. A. A., Gibson, C. M., Granger, C., Menon, V., Montalescot, G., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1609581 · Cited by 801
Cited by
Reading, C. L., Ahlem, C. N., & Murphy, M. F. (2021) · Neurodegenerative Disease Management · doi:10.2217/nmt-2021-0022 · Cited by 84
Emerging role of HDL in brain cholesterol metabolism and neurodegenerative disorders
Turri, M., Marchi, C., Adorni, M. P., Calabresi, L., & Zimetti, F. (2022) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2022.159123 · Cited by 54
Self-citationZimetti, F., Adorni, M. P., Marsillach, J., Marchi, C., Trentini, A., Valacchi, G., & Cervellati, C. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/6695796 · Cited by 49
Self-citationZuin, M., Cervellati, C., Trentini, A., Passaro, A., Rosta, V., Zimetti, F., & Zuliani, G. (2021) · Diagnostics · doi:10.3390/diagnostics11060984 · Cited by 45
“Indeed, Apo A-I has been demonstrated to cross the BBB through a transcytosis process [14] independent of clathrin, but mediated by the HDL receptor SR-BI [31], or, alternatively, through an involvement of the LDL receptor-related protein family [32].”
BackgroundInfluentialSelf-citationBorràs, C., Mercer, A., Sirisi, S., Alcolea, D., Escolà-Gil, J. C., Blanco-Vaca, F., & Tondo, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23169356 · Cited by 39
Metadata
- Authors
- Marsillach, J., Adorni, M. P., Zimetti, F., Papotti, B., Zuliani, G., & Cervellati, C.
- Venue
- Antioxidants
- Publisher
- MDPI AG
- Published
- 2020-12-03
- Volume
- 9
- Issue
- 12
- Pages
- 1224
- ISSN
- 2076-3921 (ISSN-L)
- OpenAlex
- W3109695053
- Cited by
- 54
- References
- 49
- FWCI
- 3.90
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: HDL Proteome and Alzheimer’s Disease: Evidence of a Link. https://app.cochat.ai/papers/10.3390/antiox9121224
- The paper
- Marsillach, J., Adorni, M. P., Zimetti, F., Papotti, B., Zuliani, G., & Cervellati, C. (2020). HDL Proteome and Alzheimer’s Disease: Evidence of a Link. Antioxidants. https://doi.org/10.3390/antiox9121224
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.